US2017267745A1PendingUtilityA1

Factor viii glycoforms

65
Assignee: BAYER HEALTHCARE LLCPriority: Dec 10, 1998Filed: Apr 5, 2017Published: Sep 21, 2017
Est. expiryDec 10, 2018(expired)· nominal 20-yr term from priority
Inventors:Myung-Sam ChoSham-Yuen Chan
A61P 7/04A61P 7/00A61K 38/00C07K 14/755C12N 2799/028C12N 5/10
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention concerns glycosylated proteins having human factor VIII activity. In a preferred embodiment, the protein is glycosylated with oligosaccharides that include an alpha-(2,6)-linked sialic acid and a bisecting GlcNAc linked to a core beta-mannose.

Claims

exact text as granted — not AI-modified
1 - 46 . (canceled) 
     
     
         47 . A method of treating a factor VIII-associated disorder comprising administering to a human in need thereof a therapeutically effective amount of a composition comprising (1) an isolated glycosylated protein having factor VIII procoagulent activity comprising an N-linked oligosaccharide having a bisecting GlcNAc linked to a core beta-mannose and (2) a pharmaceutically acceptable adjuvant. 
     
     
         48 . The method of  claim 47 , wherein the factor VIII-associated disorder is hemophilia A.

Join the waitlist — get patent alerts

Track US2017267745A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.